A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

Other illness

• Any evidence of a condition other than AD that may affect cognition, including, but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson disease, corticobasal syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration (other than frontotemporal dementia), Huntington disease, normal pressure hydrocephalus, seizure disorder, delirium, or hypoxia
• MCI (may be referred to as prodromal AD), or any form of dementia
• History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma
• History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
• Uncontrolled hypertension (e.g., blood pressure generally >160 mmHg systolic or > 95 mmHg diastolic)

Other

• Pregnancy or breastfeeding, or intending to become pregnant during the study

• Individuals aged ≥ 55 to ≤ 64 must have at least one of the following additional risk factors prior to screening: – First degree relative diagnosed with dementia onset before age 75
• Body weight of 150 kg or less
• Adequate visual and auditory acuity, in the investigator’s judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
• Cognitively and functionally unimpaired
• Agreement to adhere to the contraception requirements (highly effective methods for female participants <1% error rate)
• Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug